Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Long-term patency of regenerated neoaortic wall following the implant of a fully biodegradable polyurethane prosthesis: Experimental lipid diet model in pigs

  • 6 Accesses


The degradation of a polyurethane vascular prosthesis, the time course and characteristics of tissue ingrowth and prosthesis replacement, and the incidence of thrombosis have been investigated in 50 young pigs. A 6–7 cm long cone-shaped prosthesis was implanted in the infrarenal aorta of 50 young growing pigs which were sacrificed at intervals from 60 to 365 days. Ten animals were controls, 25 were given aspirin 10 mg/kg of body weight/day, and 15 were fed with cod liver oil. Aortography, done at 30, 60, and 90 days, showed 100% of implants were thrombosed in the surviving controls, 55% of the aspirin group had patent grafts, and 100% of animals in the lipid diet group had patent grafts. At final graft retrieval, the aspirin group showed only three patencies, while in the lipid diet group seven out of nine animals were patent. The laboratory and morphological studies indicated that all patent prostheses were lined with tissues that resembled the intima of native aorta with a layer of smooth muscle cells which appeared complete at 180 days. From these data we conclude that the biodegradable polyurethane vascular prosthesis is reliable for experimental implants in a pig model. The lipid-rich diet of polyunsaturated fatty acids potentiates long-term patency, perhaps by preventing platelet aggregation and thrombosis, and allowing the growth of a neoendothelium and neomedia within the lumen of the prosthesis, which slowly degrade towards fatty tissue and form neoadventitia.

This is a preview of subscription content, log in to check access.


  1. 1.

    EDWARDS WH, EDWARDS Jr WH, MULHERIN Jr JL, JENKINS JM. The role of antiplatelet drugs in carotid reconstruction surgery.Ann Surg 1985;201:765–770.

  2. 2.

    SALZMAN EW. Role of platelets in blood-surface interaction.Fed Proc 1971;30:1503–1509.

  3. 3.

    GALLETTI G, USSIA G, FAENZA A, RUSCELLI P, CAVUCCHI G, SALERNO A, De MARTINO L, LIVANI FM, FARRUGGIA F. New criteria to evaluate tissue reactivity and failure of artificial prosthesis.Ettrop Surg Res 1983;15(S1):104.

  4. 4.

    YATES SG, NAKAGAWA Y, BERGER K, SAUVAGE LR. Surface thrombogenicity of arterial prostheses.Surg Gynecol Obstet 1973;136:12–16.

  5. 5.

    DARIUS H, LEFER DJ, SMITH JB, LEFER AM. Role of platelet activating factor-aceter in mediating guinea pig anaphylaxis.Science 1986;232:58–60.

  6. 6.

    EVANS G, MUSTARD JF. Platelet-surface reaction and thrombosis.Surgery 1968;64:273–280.

  7. 7.

    FISHER AC, HOW TV, De COSSART L, ANNIS D. The longer term patency of a compliant small diameter arterial prosthesis: the effects of withdrawing of aspirin and dipyridamol therapy: the effect of reduced compliance.Trans Am Soc Art Intern Organs 1985;31:324–328.

  8. 8.

    CASALI RE, HALE JA, LE NARZ LR, FAAZ F, MORRIS MD. Improved graft patency with altered platelet function induced by marine fatty acids in dogs.J Surg Res 1986;40:6–12.

  9. 9.

    SEEGER JM, KLINGMAN N. Improved endothelial cell seeding with cultured cells and fibronectin-coated grafts.J Surg Res 1985;55:641–647.

  10. 10.

    PLATE G, HOLLIER LH, FOWL RJ, SANDE JR, KAYE MP. Endothelial seeding of venous prostheses.Surgery 1984;96:929–935.

  11. 11.

    WEINBERG CB, BELL E. A blood vessel model constructed from collagen and cultured vascular cells.Science 1986;231:397.

  12. 12.

    KINLEY CE, MARBLE AE. Compliance: a continuing problem with vascular grafts.J Cardiovasc Surg 1980;21:163.

  13. 13.

    KARDOS JL, METHA BS, APOSTOLOU SF, THIES C, CLARK RE. Prosthetic blood vessels.Biomat Med Dev Art Organs 1974;2:387.

  14. 14.

    LYMAN DJ, ALBO Jr D, JACKSON R, KNUTSON K. Development of small diameter vascular prosthesis.Trans Am Soc Artiflnt Organs 1977;18:253.

  15. 15.

    RUDERMAN RJ, HEGYELY AF, HATTLER BG, LEONARD F. A partially degradable vascular prosthesis.Trans Am Soc Artiflnt Organs 1972;18:37.

  16. 16.

    GOGOLEWSKI S, PENNINGS AJ. Biodegradable materials of polylactide.Macromol Chem Rapid Commun 1982;5:839.

  17. 17.

    GALLETTI G, USSIA G, GOGOLEWSKI S, GIARDINO R, SALERNO A, LEONARDI L, GUIZZARDI S. Polyurethane degradable vascular prosthesis. A long term experimental study in pigs.Europ Surg Res 1985;17(S1):16.

  18. 18.

    GALLETTI G, GOGOLEWSKI S, USSIA G, GIARDINO R, SALERNO A, GRILLI-CICILIONI C, GUIZZARDI S. Ultrastructural study of the tissue substitutes growing on the degradable vascular prosthesis.Europ Surg Res 1986;18(S1): 78.

  19. 19.

    GOGOLEWSKI S, GALLETTI G. Microporous, compliant vascular prosthesis of adjustable rate of degradation. Proc ESAO, Alpbach, Innsbruck, Austria, September 9–12, 1984.

  20. 20.

    GOGOLEWSKI S, GALLETTI S. Degradable microporous vascular prosthesis from segmented polyurethane.Colloid & Polymer Sci 1986;264:854.

  21. 21.

    GALLETTI G, USSIA G, FARRUGGIA F, GIARDINO R, GOGOLEWSKI S. Arterial replacement with a degradable vascular prosthesis.Life Supp Systems 1986;4(S2):74.

  22. 22.

    GOGOLEWSKI S, GALLETTI G, USSIA G. Polyurethane vascular prosthesis in pigs.Colloid & Polymer Sci 1987;265:774–778.

  23. 23.

    HIRSH J. The optimal antithrombotic dose of aspirin.Arch Intern Med 1985;145:1582–1583.

  24. 24.

    HEPBURN FN, EXLER J, WEIHRAUCH JL. Provisional tables on the content of omega-3 fatty acids and fat components of selected foods.J Am Dietetic Assoc 1986;56: 788–794.

  25. 25.

    SOBEL M, ADELMAN B, GREENFIELD LJ. Dextran 40 reduces heparin-mediated platelet aggregation.J Surg Res 1986;40:382–387.

  26. 26.

    BERK BC, ALEXANDER RW, BROCK TA, GIMBRONE MA, CLINTON WEBB Jr R. Vasoconstriction: a new activity for platelet-derived growth factor.Science 1986;232:87–89.

  27. 27.

    DUNNE JR, et al. Diseases of swine. The Iowa State University Press, Ames, Iowa, 1975.

  28. 28.

    SCHACKY C, FISCHER S, WEBER PC. Long-term effects of dietary marine cn-3 fatty acids upon plasma and cellular lipids, platelet function and eicosanoids formation in humans.J Clin Invest 1985;76:1626–1631.

  29. 29.

    MARTZ H, PAYNTER R, FOREST JCL, DOWNS A. GUIDOIN R. Microporous hydrophilic polyurethane vascular grafts as substitutes in the abdominal aorta of dogs.Biomaterials 1987;5:3–11.

  30. 30.

    MONCADA S, HIGGS EA, VANE JR. Human arterial and venous tissues generate prostacyclin (prostaglandin X) a potent inhibitor of platelet aggregation.Lancet 1977;7:18–20.

  31. 31.

    SALMON JA. A radioimmunoassay of 6-keto-prostaglandin Fla.Prostaglandins 1978;15:383–387.

  32. 32.

    LASCHI R. Contribution of scanning electron microscopy and associated analytical techniques to the study of arteriosclerotic disease.Scan Electr Microscopy 1985;3:1215–1222.

  33. 33.

    RICHARDSON M, HATTON MWC, BUCHANON MR, MOORE S. Scanning electron microscopy of normal rabbit aorta: injury or artifact?J Ultrastruct Res 1985;91:159–173.

  34. 34.

    MATHIEU-COSTELLO O, FRONEK K. Morphometry of the amount of smooth muscle cells in the media of various rabbit arteries.J Ultrastruct Res 1985;91:1–12.

  35. 35.

    NETER J, WASSERMAN W. Applied linear statistical models. Part III: basic analysis of variance. Homewood, RD Irwin, Inc., 1974;4l9–545.

  36. 36.

    WESOLOWSKI SA, FRIED CC, DOMINGO RT, LIEBIG WJ, SAWYER PN. The compound prosthetic vascular graft. A pathologic survey.Surgery 1963;53:19–44.

  37. 37.

    BOWALD S, BUSCH C, ERIKSSON I. Arterial regeneration following polyglactin 910 suture mesh grafting.Surgery 1979;56:722–728.

  38. 38.

    METKE MP, LIE JT, FUSTER V, JOSA M, KAYE MP. Reduction of intimai thickening in canine coronary bypass vein grafts with dipyridamole and aspirin.Am J Cardiol 1979;43:1144–1148.

  39. 39.

    GALLETTI PM, AEBISCHER P, SASKEN HF, GODDARD M, CHIN TH. Experience with fully bioresorbable aortic grafts in the dog.Surgely 1988;103:231–241.

  40. 40.

    WEBER PC, FISHER S, SCHACKY CV, LORENZ R, STRASSER T. The conversion of dietary eicosapentaenoic acid to prostanoids and leukotriens in man.Prog Lipid Res 1986;25:173–176.

  41. 41.

    HIGGS EA, MONCADA S, VANE JR. Prostaglandins and thromboxanes from fatty acids.Prog Lipid Res 1986;25: 5–11.

  42. 42.

    LEE AG, EAST JM, FROUD RJ. Are essentia] fatty acids essential for membrane function?Prog Lipid Res 1986;25: 41–46.

  43. 43.

    TORANO T, HIRAI A, TAMURA Y, YOSHIDA S, SALMON JA, MONCADA S. Effect of eicosapentaenoic acid on eicosanoids formation by stimulated human polymorphonnucleate leukocytes.Prog Lipid Res 1986;25:129–137.

  44. 44.

    GOGOLEWSKI S, GALLETTI G, USSIA G. Degradable small caliber vascular prosthesis.Proc 11th Annual Meeting Soc Biomaterials, San Diego, California, USA, April 24–28, 1985;7:187.

Download references

Author information

Correspondence to Giovanni Galletti MD.

About this article

Cite this article

Galletti, G., Gogolewski, S., Ussia, G. et al. Long-term patency of regenerated neoaortic wall following the implant of a fully biodegradable polyurethane prosthesis: Experimental lipid diet model in pigs. Annals of Vascular Surgery 3, 236–243 (1989). https://doi.org/10.1007/BF03187401

Download citation

Key words

  • Aorta
  • polyurethane
  • vascular prosthesis
  • biodegradable grafts
  • suture materials
  • endothelialization
  • polyunsaturated n-3 fatty acids